BRUKINSA® Chronic Lymphocytic Leukaemia (CLL)

This is a promotional website intended for healthcare professionals in the UK and Ireland only.

BRUKINSA®▼ as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).1

The efficacy of BRUKINSA in the treatment of CLL has been demonstrated both as first-line treatment, and for relapsed/refractory CLL with clinical benefit observed across major CLL subtypes.1–4

BRUKINSA demonstrated superior efficacy and safety compared with ibrutinib, the first-generation BTK inhibitor, in patients with relapsed/refractory CLL.3,4

BRUKINSA has a favourable safety and tolerability profile.1–4 A lower incidence of treatment discontinuation for any reason was observed with BRUKINSA compared with ibrutinib, including adverse events, cardiac events and progressive disease.3,4

The use of BRUKINSA as monotherapy for the treatment of adult patients with CLL is supported by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the Health Service Executive (HSE) in Ireland.5–7

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at www.mhra.gov.uk/yellowcard.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA.

All adverse events (UK and Ireland) should also be reported to BeiGene at [email protected]; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

February 2024 [0823-BRU-PRC-157_v2]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not